Status message

Active context: kki_bg_colors_yellow

A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Principal Investigator:

To evaluate the long-term safety and tolerability of SEP-225289 in adult subjects with ADHD by the incidence of adverse events (AEs; or serious AEs), AEs (or SAEs) leading to discontinuation.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.